In December 2009 Javelin & Hospira gave the FDA a NDA for an injectable diclofenac. Multiple amendments,emails, and years later it was approved for mono therapy or combo therapy for moderate or severe pain in December 23, 2014. 
Post marketing studies in the 1-16 year old population will be forthcoming in the next 4-5 years. 
Source: Drugs@FDA